Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Rating Reaffirmed by JMP Securities

JMP Securities restated their market outperform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research report sent to investors on Friday morning, Benzinga reports. The brokerage currently has a $22.00 target price on the biotechnology company’s stock.

ENTA has been the subject of several other research reports. Evercore ISI raised shares of Enanta Pharmaceuticals to a strong-buy rating in a research report on Tuesday, August 6th. JPMorgan Chase & Co. lowered their price objective on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an underweight rating for the company in a research report on Tuesday, August 6th. Finally, HC Wainwright reiterated a buy rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of Hold and an average price target of $19.00.

Enanta Pharmaceuticals Stock Down 4.0 %

Shares of NASDAQ:ENTA opened at $10.05 on Friday. Enanta Pharmaceuticals has a 52-week low of $8.08 and a 52-week high of $17.80. The company has a 50 day moving average of $12.70 and a two-hundred day moving average of $13.44. The company has a market capitalization of $212.85 million, a price-to-earnings ratio of -1.61 and a beta of 0.59.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative net margin of 160.27% and a negative return on equity of 63.75%. The company had revenue of $17.97 million during the quarter, compared to the consensus estimate of $17.44 million. During the same quarter last year, the company earned ($1.27) earnings per share. Enanta Pharmaceuticals’s revenue for the quarter was down 4.9% on a year-over-year basis. On average, equities analysts anticipate that Enanta Pharmaceuticals will post -5.3 earnings per share for the current year.

Insider Activity

In related news, insider Scott T. Rottinghaus sold 5,375 shares of the firm’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $17.08, for a total transaction of $91,805.00. Following the transaction, the insider now directly owns 21,717 shares in the company, valued at $370,926.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Scott T. Rottinghaus sold 5,375 shares of the firm’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $17.08, for a total transaction of $91,805.00. Following the transaction, the insider now directly owns 21,717 shares in the company, valued at $370,926.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Scott T. Rottinghaus sold 4,299 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $15.07, for a total value of $64,785.93. Following the transaction, the insider now owns 23,988 shares in the company, valued at $361,499.16. The disclosure for this sale can be found here. Company insiders own 13.64% of the company’s stock.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC bought a new stake in Enanta Pharmaceuticals in the second quarter valued at $35,000. State Board of Administration of Florida Retirement System bought a new stake in Enanta Pharmaceuticals in the first quarter valued at $118,000. Quest Partners LLC lifted its stake in Enanta Pharmaceuticals by 511.2% in the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 9,692 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Enanta Pharmaceuticals during the first quarter valued at $191,000. Finally, Pennant Investors LP acquired a new position in shares of Enanta Pharmaceuticals during the fourth quarter valued at $330,000. 94.99% of the stock is currently owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.